Navigation Links
Statement by KCP Chairman Dr. Edward Jones in Response to FDA Advisory Committee on Benefits and Risks of Erythropoietin-Stimulating Agents in Treatment of Kidney Patients
Date:9/12/2007

September 11, 2007

WASHINGTON, Sept. 12 /PRNewswire-USNewswire/ -- The following is a statement by KCP Chairman Dr. Edward Jones:

Yesterday's FDA Advisory Committee meeting underscores the many considerations that must be factored in to policymaking related to anemia treatment in patients suffering from chronic kidney disease. The kidney community salutes FDA for working with scientists, practicing nephrologists, and other members of the medical community to achieve a consensus on hemoglobin and dosing levels for erythropoietin-stimulating agents (ESAs) based on different patient populations. The community is unified in its belief that patient quality of care and quality of life must be taken into account as physicians treat anemia in kidney patients. Patients with chronic kidney disease and those on dialysis depend on ESAs to stimulate red blood cell production in their bodies.

Anemia-management drugs have been well demonstrated to improve quality of life for kidney patients and provide significant medical benefits. Unlike patients with cancer, patients with chronic kidney disease are permanently affected by anemia, which in turn affects their ability to engage in day-to- day activities that non-patients take for granted -- caring for their families, holding a job, and going to school. Without ESA therapy, ESRD patients may develop hemoglobin levels that are dangerously low. Before ESAs were available, blood transfusions were required in most kidney patients. Transfused patients often suffered from heart failure, iron overload, and other chronic problems.

Several studies have demonstrated improvement in the morbidity and mortality of patients with kidney disease and kidney failure by the appropriate management of their anemia. After extensive review of the results of six new studies, a National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) work group updated its Clinical Practice Guidel
'/>"/>

SOURCE Kidney Care Partners
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
2. Obama Statement on Bush Veto of Stem Cell Bill
3. Statement by Philip Home Chairman of the RECORD Study Steering Committee and Professor of Diabetes Medicine at Newcastle University in England
4. New Position Statement from The North American Menopause Society Addresses Use of Local Estrogen for Treatment of Vaginal Atrophy in Postmenopausal Women
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. TMC125 Showed Significant Virologic Response at Week 24 in Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3 Trials
7. Trexima (Sumatriptan/Naproxen Sodium) Demonstrated Migraine-Free Response Across Multiple Attacks
8. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
9. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
10. Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL)
11. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based on the number of ... for the second quarter ended June 30, 2015. ... , Revenue increased by 12.9% to RMB775.1 million ... quarter of 2014 , Same store sales increased ...
(Date:9/1/2015)... Delaware , United States , Sept. ... "Invion"), is pleased to announce that it has entered into ... investor in the United States in ... million ("Placement") by the issue of 71,500,000 million fully-paid ordinary ... The Company has also agreed to grant ...
(Date:9/1/2015)... and BRUSSELS , ... ) and UCB (Euronext Brussels: UCB) today announced ... effect of RomosozUmab Compared with Teriparatide in postmenopaUsal ... pReviously treated with bisphosphonatE therapy). The study (NCT01796301) ... difference in favor of romosozumab in the percent ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 10Invion Announces Private Placement to US Institutional Investor 2Invion Announces Private Placement to US Institutional Investor 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 2Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 3Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 4Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 5Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 6Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 7Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 8Amgen And UCB Announce Positive Top-Line Results From Open-Label Phase 3 Study Of Romosozumab Compared With Teriparatide 9
... hospitals scramble to adopt the patient-centered focus that is ... at improving healthcare in the U.S., LodgeNet Healthcare ... engagement solution that encourages patients to become educated, active ... to interact with patients throughout the entire continuum of ...
... EAST BRUNSWICK, N.J. and EDISON, N.J., June 8, ... today announced they had entered into a broad-based ... controlled release products. Under the terms of the ... develop and manufacture products for Amerigen to commercialize ...
Cached Medicine Technology:LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 2LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 3LodgeNet Healthcare's eSUITE Solution Empowers Patients to Participate in Their Care 4Amerigen Pharmaceuticals and AustarPharma Enter Into Collaboration Agreement for Generic Oral Controlled Release Products 2
(Date:9/2/2015)... ... 2015 , ... On September 9, 2015, over 27,000 people from all over ... convention to date for the state of Utah. , “We are thrilled with the ... David Stirling, doTERRA CEO. “One of the most exciting elements of our convention is ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... Brain Aneurysm Awareness Month , which was established by the Foundation in 2007 ... and education, and helping fund more research remains our top priority,” commented Christine ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to be ... being launched, and mobile device usage as a whole is something people around the ... lives. What's more people are expecting mobile versions of their favorite software. , While ...
(Date:9/1/2015)... ... 2015 , ... September is National Prostate Cancer Awareness Month and Florida Hospital ... each year in the United States. , Prostate cancer is to men what breast ... 1 in 7 men. One new case occurs every 2.3 minutes and a man ...
(Date:9/1/2015)... Los Angeles, CA (PRWEB) , ... September 01, 2015 , ... ... the American Medical Association, individuals with type 2 diabetes that participated in a three ... of diabetes three years down the line if they elected weight loss surgery at ...
Breaking Medicine News(10 mins):Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:September is Prostate Cancer Awareness Month 2Health News:September is Prostate Cancer Awareness Month 3Health News:Recent Journal Article on Diabetes Remission Adds to the Growing Pile Of Evidence in Favor of Bariatric Surgery, Says Dr. Feiz and Associates 2
... Reinberg HealthDay Reporter , MONDAY, April 4 (HealthDay ... that accounts for most cases of cervical cancer, may also ... other smaller studies, HPV has been found in lung cancer ... the development of the disease is not known, the scientists ...
... The London School of Medicine and Dentistry and ... of mimicking the body,s natural mechanism of fighting ... termed ,microparticles, that retain features of their parent ... beneficial to health, and that these microparticles contained ...
... winners and finalists of the 2010 Prix Galien USA and ... issue of Annals of the New York Academy of ... in biopharmaceutical research, recognizes outstanding achievements in improving the global ... Established in 1970, Prix Galien is the most ...
... New guidelines issued by the American Gastroenterological Association ... to remove precancerous cells in patients with Barrett,s ... acid reflux, or GERD. Barrett,s esophagus is ... an estimated two million Americans. While traditionally ...
... country in the 1970s. Currently, there are approximately 9.5 million ... in this country annually. The rapid rise in ATV-related injuries ... of larger, faster, and more powerful vehicles, according to a ... of the Journal of the American Academy of Orthopaedic ...
... or ADHD, is widely recognized by the medical community, and ... many as six percent of all children suffer from the ... refined motor skills, children with DCD tend to have a ... They appear to be uncoordinated and many parents think ...
Cached Medicine News:Health News:HPV Might Be Linked to Lung Cancer 2Health News:Researchers mimic body's own healing potential to create personalised therapies for inflammation 2Health News:Prix Galien winners published in Annals of the New York Academy of Sciences 2Health News:Treatment of Barrett's esophagus may lower risk of esophageal cancer 2Health News:Adult-sized ATVs are not safe for kids; statistics startling 2Health News:Adult-sized ATVs are not safe for kids; statistics startling 3Health News:Clumsy kids who don't 'grow out of it' 2
... test setup, try Cadwell paired disc electrodes. ... The custom-molded contacts are 10 mm (0.4 ... solid stainless steel with a locator pin ... color coded and available in twisted pairs. ...
... Video Camera System (NTSC)With Maxenon PowerPlus ... surgeon's eye view of any procedure. ... or digital files for later use. ... 8" to 36". Automatic Iris and ...
... chloride ring electrodes fit pediatric ... with minicrocodile clip lead wires ... (4 in) long, 0.6 cm ... package contains 50 individually sealed ...
Four disposable disc electrodes are pre-gelled and attached to wires in red, blue, black and green. 4mil carbon film, Ag/AgCl coated. Each package contains 20 individually sealed sets of four leads....
Medicine Products: